Rexahn Pharmaceuticals, Inc. Announces US Patent Issued for CNS-based Treatment of Sexual Dysfunction
ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 7,998,991, entitled “Neurotherapeutic treatment for sexual dysfunction.”